PMC:7646269 / 15426-16759 JSONTXT

{"project":"LitCovid_Glycan-Motif-Structure","denotations":[{"id":"T9","span":{"begin":1234,"end":1247},"obj":"https://glytoucan.org/Structures/Glycans/G93424OB"}],"text":"All the patients with putative IPA died in our consecutive cases, suggesting the grave prognosis of critically ill patients with CAPA. On the other hand, Alanio et al reported no significant difference in mortality between IPA and non‐IPA patients in a report of eight COVID‐19‐infected patients with putative IPA. 6 Further data from multi‐institutional series are needed to clearly characterise the potential impact on mortality of CAPA. Although dexamethasone was recently shown to decrease 28‐day mortality in mechanically ventilated patients with COVID‐19, 14 the majority of our cases received much higher doses of glucocorticoids than what was proven beneficial. Since one of the potential sequelae of COVID‐19 is secondary fungal infections as our cases demonstrated, vigilance for secondary infections will be needed to reduce adverse outcomes. Clinicians should have a high index of suspicion for CAPA when a critically ill patient with COVID‐19 in the ICU develops further respiratory decompensation, fevers or new or worsening radiographic abnormalities of the lungs, particularly if there is no response to empiric antibacterial therapy. It is important to obtain a respiratory culture for fungal pathogens and a serum galactomannan level in these settings to attempt to identify this ominous complication of COVID‐19."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T29","span":{"begin":148,"end":152},"obj":"Body_part"},{"id":"T30","span":{"begin":1075,"end":1080},"obj":"Body_part"},{"id":"T31","span":{"begin":1228,"end":1233},"obj":"Body_part"}],"attributes":[{"id":"A29","pred":"fma_id","subj":"T29","obj":"http://purl.org/sig/ont/fma/fma9712"},{"id":"A30","pred":"fma_id","subj":"T30","obj":"http://purl.org/sig/ont/fma/fma68877"},{"id":"A31","pred":"fma_id","subj":"T31","obj":"http://purl.org/sig/ont/fma/fma63083"}],"text":"All the patients with putative IPA died in our consecutive cases, suggesting the grave prognosis of critically ill patients with CAPA. On the other hand, Alanio et al reported no significant difference in mortality between IPA and non‐IPA patients in a report of eight COVID‐19‐infected patients with putative IPA. 6 Further data from multi‐institutional series are needed to clearly characterise the potential impact on mortality of CAPA. Although dexamethasone was recently shown to decrease 28‐day mortality in mechanically ventilated patients with COVID‐19, 14 the majority of our cases received much higher doses of glucocorticoids than what was proven beneficial. Since one of the potential sequelae of COVID‐19 is secondary fungal infections as our cases demonstrated, vigilance for secondary infections will be needed to reduce adverse outcomes. Clinicians should have a high index of suspicion for CAPA when a critically ill patient with COVID‐19 in the ICU develops further respiratory decompensation, fevers or new or worsening radiographic abnormalities of the lungs, particularly if there is no response to empiric antibacterial therapy. It is important to obtain a respiratory culture for fungal pathogens and a serum galactomannan level in these settings to attempt to identify this ominous complication of COVID‐19."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T30","span":{"begin":148,"end":152},"obj":"Body_part"},{"id":"T31","span":{"begin":1228,"end":1233},"obj":"Body_part"}],"attributes":[{"id":"A30","pred":"uberon_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/UBERON_0002398"},{"id":"A31","pred":"uberon_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"All the patients with putative IPA died in our consecutive cases, suggesting the grave prognosis of critically ill patients with CAPA. On the other hand, Alanio et al reported no significant difference in mortality between IPA and non‐IPA patients in a report of eight COVID‐19‐infected patients with putative IPA. 6 Further data from multi‐institutional series are needed to clearly characterise the potential impact on mortality of CAPA. Although dexamethasone was recently shown to decrease 28‐day mortality in mechanically ventilated patients with COVID‐19, 14 the majority of our cases received much higher doses of glucocorticoids than what was proven beneficial. Since one of the potential sequelae of COVID‐19 is secondary fungal infections as our cases demonstrated, vigilance for secondary infections will be needed to reduce adverse outcomes. Clinicians should have a high index of suspicion for CAPA when a critically ill patient with COVID‐19 in the ICU develops further respiratory decompensation, fevers or new or worsening radiographic abnormalities of the lungs, particularly if there is no response to empiric antibacterial therapy. It is important to obtain a respiratory culture for fungal pathogens and a serum galactomannan level in these settings to attempt to identify this ominous complication of COVID‐19."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T109","span":{"begin":129,"end":133},"obj":"Disease"},{"id":"T110","span":{"begin":269,"end":277},"obj":"Disease"},{"id":"T111","span":{"begin":435,"end":439},"obj":"Disease"},{"id":"T112","span":{"begin":553,"end":561},"obj":"Disease"},{"id":"T113","span":{"begin":711,"end":719},"obj":"Disease"},{"id":"T114","span":{"begin":733,"end":750},"obj":"Disease"},{"id":"T115","span":{"begin":802,"end":812},"obj":"Disease"},{"id":"T116","span":{"begin":909,"end":913},"obj":"Disease"},{"id":"T117","span":{"begin":949,"end":957},"obj":"Disease"},{"id":"T118","span":{"begin":1324,"end":1332},"obj":"Disease"}],"attributes":[{"id":"A109","pred":"mondo_id","subj":"T109","obj":"http://purl.obolibrary.org/obo/MONDO_0007163"},{"id":"A110","pred":"mondo_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A111","pred":"mondo_id","subj":"T111","obj":"http://purl.obolibrary.org/obo/MONDO_0007163"},{"id":"A112","pred":"mondo_id","subj":"T112","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A113","pred":"mondo_id","subj":"T113","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A114","pred":"mondo_id","subj":"T114","obj":"http://purl.obolibrary.org/obo/MONDO_0002041"},{"id":"A115","pred":"mondo_id","subj":"T115","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A116","pred":"mondo_id","subj":"T116","obj":"http://purl.obolibrary.org/obo/MONDO_0007163"},{"id":"A117","pred":"mondo_id","subj":"T117","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A118","pred":"mondo_id","subj":"T118","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"All the patients with putative IPA died in our consecutive cases, suggesting the grave prognosis of critically ill patients with CAPA. On the other hand, Alanio et al reported no significant difference in mortality between IPA and non‐IPA patients in a report of eight COVID‐19‐infected patients with putative IPA. 6 Further data from multi‐institutional series are needed to clearly characterise the potential impact on mortality of CAPA. Although dexamethasone was recently shown to decrease 28‐day mortality in mechanically ventilated patients with COVID‐19, 14 the majority of our cases received much higher doses of glucocorticoids than what was proven beneficial. Since one of the potential sequelae of COVID‐19 is secondary fungal infections as our cases demonstrated, vigilance for secondary infections will be needed to reduce adverse outcomes. Clinicians should have a high index of suspicion for CAPA when a critically ill patient with COVID‐19 in the ICU develops further respiratory decompensation, fevers or new or worsening radiographic abnormalities of the lungs, particularly if there is no response to empiric antibacterial therapy. It is important to obtain a respiratory culture for fungal pathogens and a serum galactomannan level in these settings to attempt to identify this ominous complication of COVID‐19."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T75","span":{"begin":251,"end":252},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T76","span":{"begin":879,"end":880},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T77","span":{"begin":919,"end":920},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T78","span":{"begin":1075,"end":1080},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T79","span":{"begin":1179,"end":1180},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T80","span":{"begin":1226,"end":1227},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"All the patients with putative IPA died in our consecutive cases, suggesting the grave prognosis of critically ill patients with CAPA. On the other hand, Alanio et al reported no significant difference in mortality between IPA and non‐IPA patients in a report of eight COVID‐19‐infected patients with putative IPA. 6 Further data from multi‐institutional series are needed to clearly characterise the potential impact on mortality of CAPA. Although dexamethasone was recently shown to decrease 28‐day mortality in mechanically ventilated patients with COVID‐19, 14 the majority of our cases received much higher doses of glucocorticoids than what was proven beneficial. Since one of the potential sequelae of COVID‐19 is secondary fungal infections as our cases demonstrated, vigilance for secondary infections will be needed to reduce adverse outcomes. Clinicians should have a high index of suspicion for CAPA when a critically ill patient with COVID‐19 in the ICU develops further respiratory decompensation, fevers or new or worsening radiographic abnormalities of the lungs, particularly if there is no response to empiric antibacterial therapy. It is important to obtain a respiratory culture for fungal pathogens and a serum galactomannan level in these settings to attempt to identify this ominous complication of COVID‐19."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T110","span":{"begin":31,"end":34},"obj":"Chemical"},{"id":"T112","span":{"begin":223,"end":226},"obj":"Chemical"},{"id":"T114","span":{"begin":235,"end":238},"obj":"Chemical"},{"id":"T116","span":{"begin":310,"end":313},"obj":"Chemical"},{"id":"T118","span":{"begin":450,"end":463},"obj":"Chemical"},{"id":"T119","span":{"begin":623,"end":638},"obj":"Chemical"},{"id":"T120","span":{"begin":1234,"end":1247},"obj":"Chemical"}],"attributes":[{"id":"A110","pred":"chebi_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A111","pred":"chebi_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A112","pred":"chebi_id","subj":"T112","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A113","pred":"chebi_id","subj":"T112","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A114","pred":"chebi_id","subj":"T114","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A115","pred":"chebi_id","subj":"T114","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A116","pred":"chebi_id","subj":"T116","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A117","pred":"chebi_id","subj":"T116","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A118","pred":"chebi_id","subj":"T118","obj":"http://purl.obolibrary.org/obo/CHEBI_41879"},{"id":"A119","pred":"chebi_id","subj":"T119","obj":"http://purl.obolibrary.org/obo/CHEBI_24261"},{"id":"A120","pred":"chebi_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/CHEBI_27680"}],"text":"All the patients with putative IPA died in our consecutive cases, suggesting the grave prognosis of critically ill patients with CAPA. On the other hand, Alanio et al reported no significant difference in mortality between IPA and non‐IPA patients in a report of eight COVID‐19‐infected patients with putative IPA. 6 Further data from multi‐institutional series are needed to clearly characterise the potential impact on mortality of CAPA. Although dexamethasone was recently shown to decrease 28‐day mortality in mechanically ventilated patients with COVID‐19, 14 the majority of our cases received much higher doses of glucocorticoids than what was proven beneficial. Since one of the potential sequelae of COVID‐19 is secondary fungal infections as our cases demonstrated, vigilance for secondary infections will be needed to reduce adverse outcomes. Clinicians should have a high index of suspicion for CAPA when a critically ill patient with COVID‐19 in the ICU develops further respiratory decompensation, fevers or new or worsening radiographic abnormalities of the lungs, particularly if there is no response to empiric antibacterial therapy. It is important to obtain a respiratory culture for fungal pathogens and a serum galactomannan level in these settings to attempt to identify this ominous complication of COVID‐19."}

{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T9","span":{"begin":1234,"end":1247},"obj":"GlycoEpitope"}],"attributes":[{"id":"A9","pred":"glyco_epitope_db_id","subj":"T9","obj":"http://www.glycoepitope.jp/epitopes/EP0510"}],"text":"All the patients with putative IPA died in our consecutive cases, suggesting the grave prognosis of critically ill patients with CAPA. On the other hand, Alanio et al reported no significant difference in mortality between IPA and non‐IPA patients in a report of eight COVID‐19‐infected patients with putative IPA. 6 Further data from multi‐institutional series are needed to clearly characterise the potential impact on mortality of CAPA. Although dexamethasone was recently shown to decrease 28‐day mortality in mechanically ventilated patients with COVID‐19, 14 the majority of our cases received much higher doses of glucocorticoids than what was proven beneficial. Since one of the potential sequelae of COVID‐19 is secondary fungal infections as our cases demonstrated, vigilance for secondary infections will be needed to reduce adverse outcomes. Clinicians should have a high index of suspicion for CAPA when a critically ill patient with COVID‐19 in the ICU develops further respiratory decompensation, fevers or new or worsening radiographic abnormalities of the lungs, particularly if there is no response to empiric antibacterial therapy. It is important to obtain a respiratory culture for fungal pathogens and a serum galactomannan level in these settings to attempt to identify this ominous complication of COVID‐19."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T73","span":{"begin":31,"end":34},"obj":"Phenotype"},{"id":"T74","span":{"begin":223,"end":226},"obj":"Phenotype"},{"id":"T75","span":{"begin":235,"end":238},"obj":"Phenotype"},{"id":"T76","span":{"begin":310,"end":313},"obj":"Phenotype"},{"id":"T77","span":{"begin":1054,"end":1080},"obj":"Phenotype"}],"attributes":[{"id":"A73","pred":"hp_id","subj":"T73","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A74","pred":"hp_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A75","pred":"hp_id","subj":"T75","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A76","pred":"hp_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A77","pred":"hp_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/HP_0002088"}],"text":"All the patients with putative IPA died in our consecutive cases, suggesting the grave prognosis of critically ill patients with CAPA. On the other hand, Alanio et al reported no significant difference in mortality between IPA and non‐IPA patients in a report of eight COVID‐19‐infected patients with putative IPA. 6 Further data from multi‐institutional series are needed to clearly characterise the potential impact on mortality of CAPA. Although dexamethasone was recently shown to decrease 28‐day mortality in mechanically ventilated patients with COVID‐19, 14 the majority of our cases received much higher doses of glucocorticoids than what was proven beneficial. Since one of the potential sequelae of COVID‐19 is secondary fungal infections as our cases demonstrated, vigilance for secondary infections will be needed to reduce adverse outcomes. Clinicians should have a high index of suspicion for CAPA when a critically ill patient with COVID‐19 in the ICU develops further respiratory decompensation, fevers or new or worsening radiographic abnormalities of the lungs, particularly if there is no response to empiric antibacterial therapy. It is important to obtain a respiratory culture for fungal pathogens and a serum galactomannan level in these settings to attempt to identify this ominous complication of COVID‐19."}

{"project":"LitCovid-sentences","denotations":[{"id":"T158","span":{"begin":0,"end":134},"obj":"Sentence"},{"id":"T159","span":{"begin":135,"end":314},"obj":"Sentence"},{"id":"T160","span":{"begin":315,"end":440},"obj":"Sentence"},{"id":"T161","span":{"begin":441,"end":671},"obj":"Sentence"},{"id":"T162","span":{"begin":672,"end":855},"obj":"Sentence"},{"id":"T163","span":{"begin":856,"end":1152},"obj":"Sentence"},{"id":"T164","span":{"begin":1153,"end":1333},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"All the patients with putative IPA died in our consecutive cases, suggesting the grave prognosis of critically ill patients with CAPA. On the other hand, Alanio et al reported no significant difference in mortality between IPA and non‐IPA patients in a report of eight COVID‐19‐infected patients with putative IPA. 6 Further data from multi‐institutional series are needed to clearly characterise the potential impact on mortality of CAPA. Although dexamethasone was recently shown to decrease 28‐day mortality in mechanically ventilated patients with COVID‐19, 14 the majority of our cases received much higher doses of glucocorticoids than what was proven beneficial. Since one of the potential sequelae of COVID‐19 is secondary fungal infections as our cases demonstrated, vigilance for secondary infections will be needed to reduce adverse outcomes. Clinicians should have a high index of suspicion for CAPA when a critically ill patient with COVID‐19 in the ICU develops further respiratory decompensation, fevers or new or worsening radiographic abnormalities of the lungs, particularly if there is no response to empiric antibacterial therapy. It is important to obtain a respiratory culture for fungal pathogens and a serum galactomannan level in these settings to attempt to identify this ominous complication of COVID‐19."}

{"project":"LitCovid-PubTator","denotations":[{"id":"509","span":{"begin":8,"end":16},"obj":"Species"},{"id":"510","span":{"begin":115,"end":123},"obj":"Species"},{"id":"511","span":{"begin":239,"end":247},"obj":"Species"},{"id":"512","span":{"begin":287,"end":295},"obj":"Species"},{"id":"513","span":{"begin":539,"end":547},"obj":"Species"},{"id":"514","span":{"begin":936,"end":943},"obj":"Species"},{"id":"515","span":{"begin":450,"end":463},"obj":"Chemical"},{"id":"516","span":{"begin":1234,"end":1247},"obj":"Chemical"},{"id":"517","span":{"begin":35,"end":39},"obj":"Disease"},{"id":"518","span":{"begin":100,"end":114},"obj":"Disease"},{"id":"519","span":{"begin":205,"end":214},"obj":"Disease"},{"id":"520","span":{"begin":269,"end":286},"obj":"Disease"},{"id":"521","span":{"begin":422,"end":431},"obj":"Disease"},{"id":"522","span":{"begin":502,"end":511},"obj":"Disease"},{"id":"523","span":{"begin":553,"end":561},"obj":"Disease"},{"id":"524","span":{"begin":711,"end":719},"obj":"Disease"},{"id":"525","span":{"begin":740,"end":750},"obj":"Disease"},{"id":"526","span":{"begin":802,"end":812},"obj":"Disease"},{"id":"527","span":{"begin":921,"end":935},"obj":"Disease"},{"id":"528","span":{"begin":949,"end":957},"obj":"Disease"},{"id":"529","span":{"begin":1324,"end":1332},"obj":"Disease"}],"attributes":[{"id":"A509","pred":"tao:has_database_id","subj":"509","obj":"Tax:9606"},{"id":"A510","pred":"tao:has_database_id","subj":"510","obj":"Tax:9606"},{"id":"A511","pred":"tao:has_database_id","subj":"511","obj":"Tax:9606"},{"id":"A512","pred":"tao:has_database_id","subj":"512","obj":"Tax:9606"},{"id":"A513","pred":"tao:has_database_id","subj":"513","obj":"Tax:9606"},{"id":"A514","pred":"tao:has_database_id","subj":"514","obj":"Tax:9606"},{"id":"A515","pred":"tao:has_database_id","subj":"515","obj":"MESH:D003907"},{"id":"A516","pred":"tao:has_database_id","subj":"516","obj":"MESH:C012990"},{"id":"A517","pred":"tao:has_database_id","subj":"517","obj":"MESH:D003643"},{"id":"A518","pred":"tao:has_database_id","subj":"518","obj":"MESH:D016638"},{"id":"A519","pred":"tao:has_database_id","subj":"519","obj":"MESH:D003643"},{"id":"A520","pred":"tao:has_database_id","subj":"520","obj":"MESH:C000657245"},{"id":"A521","pred":"tao:has_database_id","subj":"521","obj":"MESH:D003643"},{"id":"A522","pred":"tao:has_database_id","subj":"522","obj":"MESH:D003643"},{"id":"A523","pred":"tao:has_database_id","subj":"523","obj":"MESH:C000657245"},{"id":"A524","pred":"tao:has_database_id","subj":"524","obj":"MESH:C000657245"},{"id":"A525","pred":"tao:has_database_id","subj":"525","obj":"MESH:D007239"},{"id":"A526","pred":"tao:has_database_id","subj":"526","obj":"MESH:D007239"},{"id":"A527","pred":"tao:has_database_id","subj":"527","obj":"MESH:D016638"},{"id":"A528","pred":"tao:has_database_id","subj":"528","obj":"MESH:C000657245"},{"id":"A529","pred":"tao:has_database_id","subj":"529","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"All the patients with putative IPA died in our consecutive cases, suggesting the grave prognosis of critically ill patients with CAPA. On the other hand, Alanio et al reported no significant difference in mortality between IPA and non‐IPA patients in a report of eight COVID‐19‐infected patients with putative IPA. 6 Further data from multi‐institutional series are needed to clearly characterise the potential impact on mortality of CAPA. Although dexamethasone was recently shown to decrease 28‐day mortality in mechanically ventilated patients with COVID‐19, 14 the majority of our cases received much higher doses of glucocorticoids than what was proven beneficial. Since one of the potential sequelae of COVID‐19 is secondary fungal infections as our cases demonstrated, vigilance for secondary infections will be needed to reduce adverse outcomes. Clinicians should have a high index of suspicion for CAPA when a critically ill patient with COVID‐19 in the ICU develops further respiratory decompensation, fevers or new or worsening radiographic abnormalities of the lungs, particularly if there is no response to empiric antibacterial therapy. It is important to obtain a respiratory culture for fungal pathogens and a serum galactomannan level in these settings to attempt to identify this ominous complication of COVID‐19."}